Opendata, web and dolomites

EPIMAC SIGNED

The next generation epigenetic medicine for inflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIMAC project word cloud

Explore the words cloud of the EPIMAC project. It provides you a very rough idea of what is the project "EPIMAC" about.

gsk    performance    clear    ambition    deregulated    overcome    pharmaceutical    nature    innovative    bear    worldwide    ibd    inhibitors    modifications    led    epimac    successful    treating    nicodeme    scientists    regulation    conjunction    healthcare    master    excitement    tract    gastrointestinal    al    educate    inflammatory    epigenetics    suggest    expression    generation    team    adjust    immuno    diseases    doctoral    clinical    pursue    world    etiology    kruidenier    epinova    genetics    chroma    epigenetic    people    2012    modality    environmental    train    group    regulatory    severe    units    aberrant    pharmacology    et    sme    versatile    academic    millions    skilled    precise    chronic    unclear    treatment    disease    discovery    therapeutic    therapeutics    named    inflammation    implementations    specializing    cues    2010    area    reports    bowel    hdac    strategies    cells    excellent    pipeline    preclinical    compound    time    disabling    drug    mechanisms    validation    good    gene    deacetylase    histone    multidisciplinary    companies    glaxosmithkline   

Project "EPIMAC" data sheet

The following table provides information about the project.

Coordinator
AMC MEDICAL RESEARCH BV 

Organization address
address: MEIBERGDREEF 9
city: AMSTERDAM ZUIDOOST
postcode: 1105AZ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.epimac.eu/
 Total cost 1˙294˙785 €
 EC max contribution 1˙294˙785 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-EID
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMC MEDICAL RESEARCH BV NL (AMSTERDAM ZUIDOOST) coordinator 1˙021˙497.00
2    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 273˙287.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 0.00
4    Eureka NL (Mechelen) partner 0.00
5    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) partner 0.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues. Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting millions of people worldwide. Current treatment strategies are not successful because the precise etiology unclear. It is increasingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium has the ambition to educate a group of next-generation scientists that master genetics, epigenetics, target discovery, pharmacology, preclinical validation and regulatory issues, and at the same time have a good understanding of clinical implementations of the drug pipeline of our pharmaceutical partner GSK. GSK is one of the world's leading research-based pharmaceutical and healthcare companies that aims to team up with academic partners in EPIMAC through its dedicated discovery performance unit named EpiNova in conjunction with 2 immuno-pharmacology units. An SME specializing in epigenetic compound targeting to inflammatory cells, Chroma Therapeutics, will contribute technology to EPIMAC. EPIMAC will educate and train these scientists by providing them with a versatile and multidisciplinary doctoral program, allowing them to become excellent scientists skilled to overcome the current challenges in IBD.

 Deliverables

List of deliverables.
Management, administration and finance 5d Documents, reports 2020-01-14 14:21:31
Research dissemination Other 2020-01-14 14:21:31
Management, administration and finance 5c Documents, reports 2019-07-10 15:36:56

Take a look to the deliverables list in detail:  detailed list of EPIMAC deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Andrew Y. F. Li Yim, Jessica R. de Bruyn, Nicolette W. Duijvis, Catriona Sharp, Enrico Ferrero, Wouter J. de Jonge, Manon E. Wildenberg, Marcel M. A. M. Mannens, Christianne J. Buskens, Geert R. D’Haens, Peter Henneman, Anje A. te Velde
A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn’s disease patients
published pages: e0209656, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0209656
PLOS ONE 13/12 2019-07-10
2018 Annette E. Neele, Marion J.J. Gijbels, Saskia van der Velden, Marten A. Hoeksema, Marieke C.S. Boshuizen, Koen H.M. Prange, Hung-Jen Chen, Jan Van den Bossche, Cindy P.P.A. van Roomen, Annelie Shami, Johannes H.M. Levels, Jeffrey Kroon, Tina Lucas, Stefanie Dimmeler, Esther Lutgens, Menno P.J. de Winther
Myeloid Kdm6b deficiency results in advanced atherosclerosis
published pages: 156-165, ISSN: 0021-9150, DOI: 10.1016/j.atherosclerosis.2018.05.052
Atherosclerosis 275 2019-07-10
2016 Jan Van den Bossche, Jeroen Baardman, Natasja A. Otto, Saskia van der Velden, Annette E. Neele, Susan M. van den Berg, Rosario Luque-Martin, Hung-Jen Chen, Marieke C.S. Boshuizen, Mohamed Ahmed, Marten A. Hoeksema, Alex F. de Vos, Menno P.J. de Winther
Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages
published pages: 684-696, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.09.008
Cell Reports 17/3 2019-07-10
2016 Andrew Y. F. Li Yim, Nicolette W. Duijvis, Jing Zhao, Wouter J. de Jonge, Geert R. A. M. D’Haens, Marcel M. A. M. Mannens, Adri N. P. M. Mul, Anje A. te Velde, Peter Henneman
Peripheral blood methylation profiling of female Crohn’s disease patients
published pages: , ISSN: 1868-7075, DOI: 10.1186/s13148-016-0230-5
Clinical Epigenetics 8/1 2019-07-10
2017 Vincent A. van der Mark, Mohammed Ghiboub, Casper Marsman, Jing Zhao, Remco van Dijk, Johan K. Hiralall, Kam S. Ho-Mok, Zoë Castricum, Wouter J. de Jonge, Ronald P. J. Oude Elferink, Coen C. Paulusma
Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4
published pages: 715-730, ISSN: 1420-682X, DOI: 10.1007/s00018-016-2360-5
Cellular and Molecular Life Sciences 74/4 2019-07-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIMAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIMAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

NL4XAI (2019)

Interactive Natural Language Technology for Explainable Artificial Intelligence

Read More  

Shape-IT (2019)

Supporting the interaction of Humans and Automated vehicles: Preparing for the EnvIronment of Tomorrow

Read More  

EVIDENCE (2020)

Erythrocytes properties and viability in dependence of flow and extra-cellular environment

Read More